Prulifloxacin is an older synthetic antibiotic of the fluoroquinolone drug class undergoing clinical trials prior to a possible NDA (New Drug Application) submission to the U.S. Food and Drug Administration (FDA). It is a prodrug which is metabolized in the body to the active compound ulifloxacin. It was developed over two decades ago by Nippon Shinyaku Co. and was patented in Japan in 1987 and in the United States in 1989.
It has been approved for the treatment of uncomplicated and complicated urinary tract infections, community-acquired respiratory tract infections in Italy and gastroenteritis, including infectious diarrheas, in Japan.Prulifloxacin has not been approved for use in the United States.
基本介紹
- 中文名：普利沙星(氟喹諾酮類抗菌劑)
- 外文名：Prulifloxacin
- CAS登錄號：123447-62-1
- 分子式：C21H20FN3O6S
- 分子量：461.46
產品名稱：普利沙星;普盧利沙星;6-氟-1-甲基-7-[4-(5-甲基-2-氧代-1,3-二氧雜環戊烯-4-基)-甲基-1-哌啶基]-4-氧代-4H-[1,3]硫氮雜環丁烷並[3,2-a]喹啉-3-羧酸
英文名：Prulifloxacin
別名：(+/-)-7-{4-[(Z)-2,3-Dihydroxy-2-butenyl]-1-piperazinyl}-6-fluoro-1-methyl-4-oxo-1H,4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid cyclic carbonate;
6-Fluoro-1-methyl-7-(4-(5-methyl-2-oxo-1,3-dioxelen-4-yl)methyl-1-piperazinyl)-4-oxo-4H-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic acid
分子式：C21H20FN3O6S
分子量：461.46
CAS登錄號：123447-62-1
普利沙星分子結構式：
